Pharma & Bio
Technology
Kim Deok-kyu, CEO of GeronCellVein: “The Fruits of 13 Years of Cooperation with China… PDRN Prescription Drug in Final Stages of Registration in Hainan”
GeronCellVain is knocking on the door of China’s specialty pharmaceutical market. The company is currently undergoing the registration process for its PDRN specialty drug in Hainan Province. Its strat…
- 2026-11-11 06:41:01
- Kim Seung-kwon
Business·Industry
Xcell Therapeutics Inc. Aims to Raise 8 Billion Won by Year-End… Will It Avoid the Risk of Negative Equity?
#Xcell Therapeutics Inc. is pursuing a third-party private placement worth 7 to 8 billion won to avoid the risk of negative equity by year-end. This comes after the company raised funds through a 9.5 …
- 2026-11-09 08:02:02
- KIM SAE-MI
Technology
Lunit Inc. Faces Profitability Test Amid Expectations for Summit Collaboration… Is a Break-Even Point Possible by Year-End?
Lunit Inc.(328130), a leading medical artificial intelligence (AI) company, is facing a critical test of its profitability.This comes as the company is set to announce its third-quarter earnings, whic…
- 2026-11-09 08:01:02
- Kim Seung-kwon
Lifestyle
LigaChem Biosciences Aims for LCB02A as a First-Line Treatment… What Is Its Strategy for Penetrating the 1.7 Trillion Won Market?
LigaChem Biosciences(141080)has outlined plans to develop “LCB02A,” an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), as a first-line treatment. Given LCB02A’s high safety profile, t…
- 2026-11-09 07:31:02
- Kim Jinsoo
Technology
LGCHEM,LTD’s Obesity Drug Contract: Rhythm Proposed Renegotiation First… The Price for Waiving the 7% Royalty Is
LGCHEM,LTD(051910)Although LG Chem expanded its technology export contract for a rare obesity treatment to the 1 trillion won range, it has emerged that it was actually its U.S. partner, Rhythm Pharma…
- 2026-11-09 07:26:02
- KIM SUNG-JIN
Disclosure Plus
1.7 Trillion Won in Orders with No Purchase Obligation… ROKIT HEALTHCARE Inc. Sees Total Value Drop by 355.3 Billion Won in Six Months
#ROKIT HEALTHCARE Inc.’s total order backlog for its long-term regeneration platform—which was in the 1 trillion won range when the company listed on KOSDAQ—has reportedly decreased by approximately 3…
- 2026-11-09 07:21:02
- KIM SAE-MI
Technology
Aribio Lab Surges on Merger Speculation; Seers and InBody Plunge on Earnings [K-Bio Pulse]
South Korean biotech and healthcare stocks mostly fell on November 6 amid an AI-driven market sell-off. Aribio Lab, formerly Cha Vaccine Institute, bucked the trend, gaining more than 11% on speculati…
- 2026-11-08 08:40:04
- KIM SAE-MI
Technology
ARIBIOLAB Soars Amid AI-Driven Stock Market Turmoil… SEERS and InBody Co., Ltd. Hindered by Earnings [Bio Spotlight]
On the 6th, as the domestic stock market wavered amid concerns over artificial intelligence (AI), biotech and healthcare stocks also generally failed to escape the downtrend. Amid this, ARIBIOLAB (for…
- 2026-11-08 08:40:03
- KIM SAE-MI
Technology
Investment Strategies for K-Bio Highlighted by a Portfolio Manager with a Degree in Pharmacy… “Focus on Demand from Big Pharma”
Park Song-i, Head of Korea Investment Trust Management, recently met with Edaily to discuss investment strategies for pharmaceutical and biotech stocks. (Photo: Korea Investment Trust Management)
…
- 2026-11-07 08:21:02
- Minji Son
Technology
NGenBio Hits Trading Limit; Funding Rounds for Proteina and AdBioTech [K-Bio Pulse]
South Korean biotech stocks saw sharply divergent performance on November 5. NGenBio hit the daily upper price limit after announcing a patent for leukemia diagnostic technology, while Proteina surged…
- 2026-11-07 07:52:03
- KIM SAE-MI
PHARM EDAILY
Shorts